Drug Profile
Research programme: cancer therapeutics - Eisai/FORMA
Latest Information Update: 19 Oct 2022
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; FORMA Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Oct 2022 FORMA Therapeutics has been acquired by Novo Nordisk
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Japan
- 17 Nov 2010 Early research in Cancer in Japan (unspecified route)